Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | ALOX15B | O15296 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360147 | 0.89 | ALOX15 (0.36) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL4369026 | 0.87 | KDM4E (0.43) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL4368977 | 0.84 | LIPE (0.42) | LIPE | |
| SCHEMBL4358032 | 0.83 | HSPB1 (0.46) | ESR1ESR2TTR | |
| SCHEMBL4363967 | 0.80 | MAPT (0.43) | — | |
| SCHEMBL4362064 | 0.80 | ADRB1 (0.41) | LIPE | |
| SCHEMBL4364062 | 0.79 | CSF1R (0.39) | LIPE | |
| SCHEMBL4369049 | 0.76 | KDM4E (0.44) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL4362356 | 0.76 | SLC8A1 (0.51) | — | |
| SCHEMBL4363593 | 0.76 | HRH3 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1583759-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063191-A1 | PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM | ORION CORPORATION (FI) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | ESR1 1827/4885ESR2 2281/4885TTR 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.